Fig. 3: Cloperastine suppresses oxidative phosphorylation.

A, B ROS levels of KYSE150 and KYSE450 after cloperastine treatment. Cells were treated with different doses of cloperastine (0, 2.5, 5, 10, 25 µM) and fluorescence intensity was measured at IN Cell Analyzer 6000. (*p < 0.05, **p < 0.01, ***p < 0.001) C, D JC-1 monomer and J-aggregate levels of cloperastine on KYSE150 and KYSE450 after cloperastine treatment. Cells were treated with different doses of cloperastine (0, 2.5, 5, 10, 25 µM) and fluorescence intensity was measured at IN Cell Analyzer 6000. (*p < 0.05, **p < 0.01, ***p < 0.001). E, F Protein’s level of NDUFA1, NDUFS5, and COX6B1 in KYSE150 and KYSE450 cells after treated with different doses of cloperastine (0, 2.5, 5, 10, 25 µM). G, H mRNA’s level of NDUFA1, NDUFS5, and COX6B1 in KYSE150 and KYSE450 cells after DMSO and cloperastine treatment.